medigraphic.com

2022, Número 1

<< Anterior Siguiente >>

Rev Educ Bioquimica 2022; 41 (1)


Melanoma: mecanismos de acción y de secreción del factor de crecimiento transformante beta (TGF-β)

Pérez-Calixto M, Anaya-Rubio I, Mota-López C, Macías-Silva M

Idioma: Español
Referencias bibliográficas: 37
Paginas: 18-27
Archivo PDF: 479.25 Kb.


RESUMEN

El melanoma es un cáncer de piel agresivo y mortal. La vía de señalización del factor de crecimiento transformante beta (TGF-β) actúa como supresora (etapas tempranas) o promotora (estados avanzados) del cáncer. En la presente revisión nos enfocamos en la secreción del TGF-β, el cual puede ser transportado por vesículas extracelulares (EVs) secretadas por las células tumorales para educar a otras células y promover la tumorigénesis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Shain AH & Bastian BC (2016) Frommelanocytes to melanomas. Nat. Rev. Cancer.16: 345–358.

  2. El Ghissassi F, Baan R, Straif K, Grosse Y,Secretan B, Bouvard V, Benbrahim-Talla L,Guha N, Freeman C, Galichet L & Cogliano V(2009) A review of human carcinogens partD: Radiation. Lancet Oncol. 10: 751–752.

  3. Wong D J L & Ribas A (2016) Targeted Therapyfor Melanoma. Cancer Treat. Res. 167: 251–262.

  4. Website. [https://www.cancer.org/es/cancer/cancer-de-pieltipomelanoma/acerca/estadisticas - clave.html]. Consultado 24 abril2021

  5. Schadendorf D, Fisher DE, Garbe C,Gershenwald JE, Grob JJ, Halpern A, HerlynM, Marchetti MA, McArthur G, Ribas A, RoeschA & Hauschild A (2015) Melanoma. Nat RevDis Primers 1: 15003.

  6. Perrot CY, Javelaud D, & Mauviel A (2013)Insights into the Transforming GrowthFactor-β Signaling Pathway in CutaneousMelanoma. Ann. Dermatol. 25: 135–144.

  7. Polsky D. & Cordon-Cardo C (2003) Oncogenesin melanoma. Oncogene 22: 3087–3091.

  8. Krasagakis K, Krüger-Krasagakes S, Fimmel S,Eberle J, Thölke D, von de Ohe M, MansmannU & Orfanos CE (1999) Desensitizationof melanoma cells to autocrine TGF-betaisoforms. J. Cell. Physiol. 178; 179–187.

  9. Lebrun J J (2012) The Dual Role of TGF-β inHuman Cancer: From Tumor suppression toCancer Metastasis. ISRN Mol Biol; 38: 1428.

  10. Massagué J (2008) TGFbeta in Cancer. Cell134: 215–230.

  11. Macías-Silva M, Sosa-Garrocho M (2004) ElFactor De Crecimiento Transformante Beta(TGF-β): Funciones Y Vías De Transducción.REB. 23: 3–11.

  12. Johnston CJ, Smyth DJ, Dresser D W &Maizels RM (2016) TGF-β in tolerance,development and regulation of immunity.Cellular immunology 299: 14–22.

  13. Massagué J & Ganesh K (2021) Metastasis-Initiating Cells and Ecosystems. CancerDiscovery. 11 (4): 971–994.

  14. Batlle E & Massagué J (2019) TransformingGrowth Factor-β Signaling in Immunity andCancer. Immunity 50(4): 924–940.

  15. Macías-Silva M, Abdollah S, Hoodless PA,Pirone R, Attisano L, Wrana JL (1996) MADR2is a substrate of the TGFbeta receptor andits phosphorylation is required for nuclearaccumulation and signaling. Cell. 27; 87 (7):1215-24

  16. Derynck R & Budi EH (2019) Specificity,versatility and control of TGF-β familysignaling. Sci Signal 12 (570).

  17. Hussein MR (2005) Transforming growthfactor-beta and malignant melanoma:molecular mechanisms. J Cutan Pathol. 32:389–395.

  18. Rodeck U, Bossler A, Graeven U, Fox FE,Norwell PC, Knabbe C & Kari C (1994).Transforming growth factor beta productionand responsiveness in normal humanmelanocytes and melanoma cells. CancerRes. 54: 575–581.

  19. Rodeck U, Nishiyama T & Mauviel A (1999)Independent regulation of growth and SMADmediatedtranscription by transforming growthfactor beta in human melanoma cells. CancerRes. 59: 547–550.

  20. Javelaud D, Mohammad KS, McKenna CR,Fournier P, Luciani F, Niewolna M, AndréJ, Delmas V, Larue L, Guise TA & MauvielA (2007) Stable overexpression of Smad7in human melanoma cells impairs bonemetastasis. Cancer Res. 67: 2317–2324

  21. Mohammad KS, Javelaud D, Fournier PGJ,Niewolna M, McKenna CR, Peng XH Duong V,Dunn LK, Mauviel A & Guise TA (2011) TGFbeta-RI kinase inhibitor SD-208 reduces thedevelopment and progression of melanomabone metastases. Cancer Res, 71: 175–184.

  22. Tzavlaki K, & Moustakas A. (2020) TGF-βSignaling. Biomolecules, 10(3).

  23. Tecalco-Cruz AC, Ríos-López DG, Vázquez-Victorio G, Rosales-Alvarez RE & Macías-SilvaM (2018) Transcriptional cofactors Ski andSnoN are major regulators of the TGF-β/Smad signaling pathway in health and disease.Signal Transduct Target Ther 3:15.

  24. Deheuninck J & Luo K (2009) Ski and SnoN,potent negative regulators of TGF-β signaling.Cell Research, 19: 47–57

  25. Javelaud D, van Kempen L, Alexaki VI,Le Scolan E, Luo K & Mauviel A (2011)Efficient TGF-β/SMAD signaling in humanmelanoma cells associated with high c-SKI/SnoN expression. Molecular Cancer, 10:2.

  26. Gowda R, Robertson BM, Iyer S, Barry J,Dinavahi SS & Robertson GP (2020) The roleof exosomes in metastasis and progression ofmelanoma, Cancer Treat. Rev. 85: 101975.

  27. Maacha S, Bhat AA, Jimenez L, Raza A,Harris M, Uddin S & Grivel JC (2019)Extracellular vesicles-mediated intercellularcommunication: roles in the tumormicroenvironment and anti-cancer drugresistance. Mol. Cancer 18: 5.

  28. van Niel G, D’Angelo G & Raposo G (2018)Shedding light on the cell biology ofextracellular vesicles. Nat Rev Mol Cell Biol19 (4): 213–228.

  29. Latifkar A, Hur YH, Sanchez JC, Cerione RA& Antonyak MA (2019) New insights intoextracellular vesicle biogenesis and function.J. Cell Sci: 132

  30. Xavier CPR, Caires HJ, Barbosa MA, BergantimR, Guimaraes JE & Vasconcelos MH (2020) TheRole of Extracellular Vesicles in the Hallmarksof Cancer and Drug Resistance. Cells: 9.

  31. Clayton A (2012) Cancer cells use exosomesas tools to manipulate immunity and themicroenvironment. Oncoimmunology 1:78–80.

  32. Webber J, Steadman R, Mason MD, Tabi Z &Clayton A (2010) Cancer exosomes triggerfibroblast to myofibroblast differentiationCancer Res. 70: 9621–9630

  33. Steinbichler TB, Dudás J, Riechelmann H &Skvortsova I I, (2017) The role of exosomesin cancer metastasis. Semin. Cancer Biol 44:170–181.

  34. Peinado H, Aleckovic M, Lavotshkin S, MateiI, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G,Ghajar C, Nitadori-Hoshino A, Badal K, GarciaBA, Callahan MK, Yuan J, Martins VR, Skog J,Kaplan RN, Brady MS, Wolchock JD, ChapmanPB, Kang Y, Bromberg J & Lyden D (2012).Melanoma exosomes educate bone marrowprogenitor cells toward a pro-metastaticphenotype through MET Nat Med 18: 883–891.

  35. Gajos-Michniewicz A, Duechler M & CzyzM (2014). MiRNA in melanoma-derivedexosomes Cancer Lett. 347: 29–37.

  36. Park JE, Dutta B, Tse SW, Gupta N, Tan CF, LowJK, Yeoh KW, Kon OL, Tam JP & Sze SK (2019)Hypoxia-induced tumor exosomes promoteM2-like macrophage polarization of infiltratingmyeloid cells and microRNA-mediatedmetabolic shift, Oncogene, 38:5158–73.

  37. Düchler M, Czernek L, Peczek L, Cypryk W,Sztiller-Sikorska M, Czyz M (2019) Melanoma-Derived Extracellular Vesicles Bear thePotential for the Induction of Antigen-SpecificTolerance. Cells, 8 (7):665.




2020     |     www.medigraphic.com